Other languages Bristol-Myers Squibb Company Berne S.E.

Equities

BMY

US1101221083

Delayed Berne S.E. Other stock markets 10:30:01 21/02/2024 pm IST			5-day change	1st Jan Change
44.08 ^CHF	+2.55%		-.--%	-6.91%

19/06	Bristol Myers: ex-CEO of Agilent joins Board of Directors	CF
18/06	Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil	19/06
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	19/06
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	18/06
Bristol Myers : dividendes décidés par le conseil	18/06
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	18/06
Bristol Myers : approbation de la FDA pour un traitement	14/06
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	14/06
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	14/06
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	12/06
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	12/06
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	12/06
Evotec erhält Forschungszahlung von 20 Mio USD von Myers Squibb	12/06
Geron shares surge after U.S. FDA approves blood disorder drug	07/06
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	04/06
Bristol Myers : résultats positifs dans le cancer du foie	04/06
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial	04/06
Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies	03/06
Bristol Myers Squibb?S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting	03/06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 11:36 pm IST